These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 26016056)
1. Interstitial pneumonitis after treatment for hepatitis C virus infection. Botnaru V; Munteanu O; Rusu D Pneumologia; 2015; 64(1):46-50. PubMed ID: 26016056 [TBL] [Abstract][Full Text] [Related]
2. [Respiratory function impairment during treatment of chronic hepatitis C with peginterferon alfa2 and ribavirin. Two cases presentation]. Biedroń-Machura M; Musialik J; Sozańska E; Zbroszczyk M; Baron J; Błońska-Fajfrowska B; Pierzchała W Wiad Lek; 2012; 65(4):232-8. PubMed ID: 23654144 [TBL] [Abstract][Full Text] [Related]
3. Pulmonary complications of treatment with pegylated interferon for hepatitis C infection-two case reports. Hegade VS; Sood R; Saralaya D; Moreea S Ann Hepatol; 2013; 12(4):629-33. PubMed ID: 23813142 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous occurrence of pleural effusion and interstitial pneumonitis after treatment with pegylated interferon for hepatitis C virus infection. Ji F; Li Z; Xue H; Liu L; Deng H South Med J; 2011 Feb; 104(2):140-2. PubMed ID: 21206334 [TBL] [Abstract][Full Text] [Related]
5. Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report. Tamaki K; Okubo A World J Gastroenterol; 2015 Jan; 21(3):1009-13. PubMed ID: 25624738 [TBL] [Abstract][Full Text] [Related]
6. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C. Ishikawa T; Kubota T; Abe H; Hirose K; Nagashima A; Togashi T; Seki K; Honma T; Yoshida T; Kamimura T Hepatogastroenterology; 2012 Oct; 59(119):2260-3. PubMed ID: 23435141 [TBL] [Abstract][Full Text] [Related]
7. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. Foster GR; Zeuzem S; Pianko S; Sarin SK; Piratvisuth T; Shah S; Andreone P; Sood A; Chuang WL; Lee CM; George J; Gould M; Flisiak R; Jacobson IM; Komolmit P; Thongsawat S; Tanwandee T; Rasenack J; Sola R; Messina I; Yin Y; Cammarata S; Feutren G; Brown KK J Viral Hepat; 2013 Apr; 20(4):e115-23. PubMed ID: 23490379 [TBL] [Abstract][Full Text] [Related]
8. [Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review]. Cacopardo B; Pinzone MR; Nunnari G Infez Med; 2013 Mar; 21(1):40-44. PubMed ID: 23524900 [TBL] [Abstract][Full Text] [Related]
9. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Chen YC; Lu SN; Lin MC Chang Gung Med J; 2007; 30(1):92-7. PubMed ID: 17477035 [TBL] [Abstract][Full Text] [Related]
10. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C]. Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081 [TBL] [Abstract][Full Text] [Related]
11. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Slavenburg S; Heijdra YF; Drenth JP Dig Dis Sci; 2010 Mar; 55(3):579-85. PubMed ID: 19399621 [TBL] [Abstract][Full Text] [Related]
12. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them]. Iwasaki Y; Ikeda F; Yamamoto K Nihon Rinsho; 2011 May; 69 Suppl 4():215-20. PubMed ID: 22096922 [No Abstract] [Full Text] [Related]
13. A case of irreversible leukoencephalopathy in a patient with C virus hepatitis treated with pegylated interferon-alpha-2b and ribavirin. Iacob SA; Petrescu AM; Iacob DG Rom J Intern Med; 2013; 51(3-4):197-200. PubMed ID: 24620633 [TBL] [Abstract][Full Text] [Related]
14. Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report. Carrillo-Esper R; González-Avila D; Uribe-Ríos M; Méndez-Sánchez N Ann Hepatol; 2008; 7(1):87-90. PubMed ID: 18376374 [TBL] [Abstract][Full Text] [Related]
15. Side effects of antiviral therapy in hepatitis C virus infection-sarcoidosis - case report. Teodor D; Teodor A; Grigore L; Jugănariu G; Dorobăţ CM; Miftode E; Azoicăi D Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1039-43. PubMed ID: 23700885 [TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population. Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572 [TBL] [Abstract][Full Text] [Related]
17. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]. Hunyady B; Kovács B; Battyáni Z Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373 [TBL] [Abstract][Full Text] [Related]
18. Concurrent acute interstitial pneumonia and pulmonary embolism during treatment with peginterferon alpha-2a and ribavirin in a patient with hepatitis C. Coban H; Yahyaoglu M; Vatan MB Indian J Pharmacol; 2014; 46(4):443-5. PubMed ID: 25097288 [TBL] [Abstract][Full Text] [Related]
19. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin. Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173 [No Abstract] [Full Text] [Related]
20. Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C. Arora A; Vargas L; Kuzniar TJ J Hosp Med; 2009 Sep; 4(7):E45-6. PubMed ID: 19753589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]